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Background: Altered gene methylation, regulated by DNA methyltransferases (DNMT) 1, 3a and 3b, contributes to
tumorigenesis. However, the role of DNMT in pancreatic ductal adenocarcinoma (PDAC) remains unknown.
Methods: Expression of DNMT 1, 3a and 3b was detected in 88 Pancreatic ductal adenocarcinoma (PDAC) and 10
normal tissue samples by immunohistochemistry. Changes in cell viability, cell cycle distribution, and apoptosis of
PDAC cell lines (Panc-1 and SW1990) were assessed after transfection with DNMT1 and 3b siRNA. Levels of CDKN1A,
Bcl-2 and Bax mRNA were assessed by qRT-PCR, and methylation of the Bax gene promoter was assayed by
methylation-specific PCR (MSP).
Results: DNMT1, 3a and 3b proteins were expressed in 46.6%, 23.9%, and 77.3% of PDAC tissues, respectively, but
were not expressed in normal pancreatic tissues. There was a co-presence of DNMT3a and DNMT3b expression and
an association of DNMT1 expression with alcohol consumption and poor overall survival. Moreover, knockdown of
DNMT1 and DNMT3b expression significantly inhibited PDAC cell viability, decreased S-phase but increased G1-phase
of the cell cycle, and induced apoptosis. Molecularly, expression of CDKN1A and Bax mRNA was upregulated, and the
Bax gene promoter was demethylated. However, a synergistic effect of combined DNMT1 and 3b knockdown was
not observed.
Conclusion: Expression of DNMT1, 3a and 3b proteins is increased in PDAC tissues, and DNMT1 expression is
associated with poor prognosis of patients. Knockdown of DNMT1 and 3b expression arrests tumor cells at the G1
phase of the cell cycle and induces apoptosis. The data suggest that DNMT knockdown may be a novel treatment
strategy for PDAC.
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Pancreatic cancer is the fourth most common cause of
cancer death in the world. Pancreatic ductal adenocarcin-
oma (PDAC) accounts for 95% of pancreatic cancer. To
date, most PDAC patients are diagnosed at advanced
stages and die within 6–12 months. The overall 5-year sur-
vival rate for pancreatic adenocarcinoma is approximately
6% [1,2]. The risk factors for PDAC include cigarette* Correspondence: lishude57@126.com; lizhaoshen111@gmail.com
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reproduction in any medium, provided the orsmoking, heavy alcohol consumption, family history,
chronic pancreatitis, and diabetes mellitus [3]. Other in-
consistent risk factors include coffee, meat and fish con-
sumption [3,4]. In addition, epidemiological evidence
increasingly suggests that environmental exposures in-
duce epigenetic modifications, altering the expression of
tumor suppressor genes and oncogenes, which may be
causal for pancreas tumorigenesis [5].
Altered DNA methylation, such as global hypomethyla-
tion or regional hypermethylation, is one of the most
consistent epigenetic changes in human cancer. Promoter
hypermethylation of tumor suppressor genes is the most
common epigenetic change observed in human cancers.. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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responsible for DNA methylation have been identified in
mammalian cells. DNMT1 is primarily a DNA mainten-
ance methyltransferase, as it methylates hemimethylated
DNA during DNA replication in vitro and in vivo [6].
DNMT3a and DNMT3b are de novo methyltransferases
and show similar activity on unmethylated and hemi-
methylated DNA [7,8]. Additionally, DNMT2 contains
the full set of C-terminal catalytic domain conserved motifs,
but it lacks the N-terminal regulatory domain characteristic
of eukaryotic DNMT [9]. The methyltransferase activity of
the recombinant DNMT2 protein is weak in vitro and
in vivo [10].
Overexpression of DNMT1 3a, and 3b has been re-
ported in a variety of cancers, such as gastric, hepatocel-
lular, colorectal, endometrioid, prostate, breast, lung
cancers, and cervical cancer [11-14]. In PDAC tissues,
aberrant expression of DNMT1 and DNMT3a proteins
[15-18], as well as DNMT1, 3a and 3b mRNA has been
reported [19]. However, some inconsistencies were re-
ported regarding the association with clinicopathological
features and prognosis due to a small sample size. Add-
itionally, there have been no reports regarding biological
behavior alterations of PDAC cells after knockdown of
DMNT expression and the underlying molecular events
in vitro. Thus, in this study, we analyzed the expression
of DNMT1, DNMT3a and DNMT3b proteins in PDAC
tissue specimens and investigated their association with
clinicopathological features and patient survival. Then,
we knocked down DNMT expression using siRNAs to
assess the effects on the regulation of biological behavior
of PDAC cells and the underlying molecular mechanisms.
Materials and methods
Patients and tissue samples
Eighty-eight PDAC patients who had a surgically resected
pancreas between January 2007 and June 2009 at the
Changhai Hospital of the Second Military Medical
University were recruited. None of the patients received
preoperative chemotherapy or radiotherapy. Tumor and
adjacent normal tissue specimens were collected in ac-
cordance with Human Subject Guidelines of the University
of Washington, and this study was approved by our
Institutional Review Board. The clinicopathological param-
eters included age, gender, smoking, alcohol consumption,
serum CEA, serum CA199, location of tumor, size of
tumor, nerve infiltration, metastasis of lymph nodes, tumor
differentiation, and TNM staging. The post-surgery follow-
up was conducted quarterly until January 2012. Tobacco
smoking was defined as at least one cigarette per day for
no less than one year. Alcohol consumption was defined as
a one-time intake of at least 50 g of Chinese liquor, 250 ml
of wine or 500 ml of beer at least once a week for a mini-
mum of 1 year.Immunohistochemistry
Serial tissue sections (4 ìm thickness) were prepared from
paraffin-embedded tissue blocks. The sections were
deparaffinized and rehydrated, and then endogenous per-
oxidase activity was blocked with 3% hydrogen peroxide
solution for 5 min and subjected to antigen retrieval in a
microwave oven at 95°C for 12 min by immersion in antigen
retrieval solution (10 mM sodium citrate buffer, pH 6.0).
This was followed by a blocking step with 1% fetal calf
serum for 20 min at room temperature. After that, the
sections were incubated overnight at 4°C with a primary
antibody including a rabbit polyclonal anti-DNMT1 anti-
body (1:100; Abcam, #ab19905), an anti-DNMT3a anti-
body (1:100; Abcam, #ab4897), or a mouse polyclonal
anti-DNMT3b antibody (1:100; IMGENEX, #IMG-184A)
followed by incubation with a secondary antibody (anti-
mouse or anti-rabbit/ Universal Immuoperoxidase Polymer,
1:200 dilution, DAKO company, USA) at room temperature
for 45 to 60 min. DAB was used for color reaction and
Mayer’s hematoxylin for counterstaining. Breast and colon
cancer tissue sections known for elevated DNMT1, 3a, and
3b expression were used as a positive control, as recom-
mended by the manufacturer’s instruction. The specificity of
DNMT1, 3a and 3b was verified by replacing the primary
antibody with a normal serum.
Two pathologists (JZ and XM), blinded to the clinico-
pathological data of each section, reviewed and scored
the stained sections. Nuclear staining was considered a
positive stain for DNMT1, 3b, and 3a. The different
staining density regions, including high, moderate, low
and negative staining areas, were captured with a digital
camera (Olympus U-TV0.5XC-3, 6B05290, Japan). Each
region was counted for a mean of 1,000 tumor cells per
case (range, 800 to 1500). According to previous studies,
a section with ≥ 20% positively stained tumor cells was
defined as positive protein expression [17,20]. Color in-
tensity was not evaluated because the stains of DNMT1,
3a, and 3b in most of the samples had similar color
intensity.
PDAC cell line and culture
The poorly differentiated PDAC cell line Panc-1 and the
well-differentiated cell line SW1990 were obtained from
ATCC (Manassas, VA). Cells were cultured in 96-well or
6-well tissue culture plates in Dulbecco’s modified
Eagle’s medium (DMEM, Invitrogen, Carlsbad, CA, USA)
containing 10% fetal bovine serum (FBS, Invitrogen) at
37°C and 5% CO2.
RNA isolation and quantitative-reverse transcription poly-
merase chain reaction (qRT-PCR)
Total RNA was isolated using a Trizol reagent (Invitrogen)
and was then reversely transcribed into cDNA using
a PrimeScriptTM RT kit (TakaRa, Dalian, China). The
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and 18S was detected by qPCR (primers are listed
in Additional file 1: Table S1) in ABI7500 (Applied
Biosystems, Foster City, CA, USA). The program had an
initial denaturation at 95°C for 1 min followed by 40 cycles
of 95°C for 15 s and 60°C for 15 s. The relative quantity
(RQ) was determined using the 2(−ÄÄCt) method, 18S
mRNA was used as reference gene, and each experiment
was repeated six or eight times.
Construction of DNMT siRNA vectors and gene
transfection
The DNMT1 and 3b-specific siRNA duplexes were chosen
from the GenBank sequences (accession #NM_001379.1
and #NM_175849.1, respectively) and synthesized by
Ambion Inc. (Austin, TX, USA). The DNMT1 siRNA se-
quences were 5′-GGAUGAGAAGAGACGUAGAtt-3′ andFigure 1 Nuclear immunostaining of DNMT1, DNMT3a and DNMT3b p
magnification: x200).5′-UCUACGUCUCUUCUCAUCCtg-3′, and the DNMT3B
siRNA sequences were 5′-GCUCGUCUCCUAUCGAAA
Att-3′ and 5′-UUUUCGAUAGGAGACGAGCtt-3′. Nega-
tive control siRNA was also purchased from Ambion Inc.
(Catalog #4390843). Final concentrations were 7 nM. The
OptiMEM (Gibco BRL Inc.) and Lipofectamine 2000
Transfection Kits (Invitrogen) were used for siRNA
transfections. Cells were plated at 1 × 105 cells per well
in culture dishes for overnight growth and transfected by
siRNA on the following day. Six hours after transfection,
the medium was removed and replaced with DMEM, and
the cells were allowed to grow for 48h. Then, viability,
apoptosis, cell cycle and gene expression were assayed.
Protein extraction and western blot
Total cellular protein was extracted from cells using an
M-PER mammalian protein extraction buffer (Pierce,roteins in normal pancreatic and PDAC tissues (Original
Figure 2 Kaplan-Meier survival curves of overall survival in
PDAC patients (N = 66) according to DNMT1 expression.
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samples were subjected to sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE, 12%) and elec-
tronically transferred onto PVDF membranes (Millipore,
Billerica, MA, USA). The membranes were incubated with
an anti-DNMT1 antibody (1:250, Abcam, Cambridge,
MA, USA), an anti-DNMT3b (1:250, Imogene, Italy) or an
anti-â-actin (1:5000, Sigma, St Louis, MO, USA) antibody
at 4°C overnight, followed by a secondary antibody for 2 h
at room temperature. The protein bands were detected
with enhanced chemiluminescence (ECL) reagent (Pierce).
Cell viability Tetrazolium Salt-8 (WST-8) assay
Briefly, cells were transfected with DNMT1, DNMT3B
or negative control siRNA oligonucleotides. Seventy-two
hours later, 10 ìl of WST-8 reagent was added to each
well and incubated for an additional 4 h. The absorbance
rate was then measured at 450 nm with an ELISA plate
reader (Thermo ELISA Reader, USA).
Flow cytometry assay
Apoptosis levels were detected using flow cytometry
(Becton Dickinson) with an Annexin V-FITC Kit (Jingmei
Biotech Company, Shanghai, China), while cell cycles
were analyzed with propidium iodide (PI) staining.
Methylation-specific PCR (MSP)
Genomic DNA was extracted from cultured cells using a
standard proteinase K and phenol-chloroform extraction
protocol. One microgram of genomic DNA was sub-
jected to treatment with the EZ DNA Methylation Kit™
(Zymo Research, Orange, CA, USA) according to the
manufacturer′s instructions. The bisulfite modified DNA
was then suspended in 20 ìl of deionized water and used
immediately or stored at −80°C until use. Two microliters
of the bisulfite modified DNA from each sample was
used as templates for methylation and unmethylation re-
actions. The primers of methylation-specific PCR se-
quences of Bax gene are shown in Additional file 1: Table
S2. The PCR conditions were as follows: 95 C hot start
for 5 min, then 40 repetitive cycles of denaturation (95 C
for 30 s), annealing (56 C for 30 s for methylation detec-
tion, 53 C for 30 s for unmethylation detection), exten-
sion (72 C 30 s), and a final 5 min extension at 72 C.
PCR products (20 ìL) were resolved on a 2% agarose gel.
Statistical analysis
Statistical analysis was performed with SPSS version 13
(SPSS Inc., Chicago, IL). The correlation among expres-
sion of the three DNMTs was analyzed with a Kendall′s
tau-b test. The correlation between the positive rate of
DNMT expression and the clinicopathological character-
istics of PDAC patients, as well as the difference of the
variables (such as expression of DNMT1 and DNMT3bmRNA vs. tumor cell viability, apoptosis and cell cycle
distribution, and expression of CDKN1A, Bcl-2, and
Bax mRNA) between the differential siRNA trans-
fected groups, were analyzed with a Mann–Whitney U
test. Univariate survival analysis was performed with a
Kaplan-Meier log-rank test, while multivariate survival
analysis was performed with a Cox Regression test. A
two-tailed P < 0.05 was considered statistically significant.
Results
Aberrant expression of DNMT1, 3a and 3b in PDAC
tissues
Positive staining of DNMT1, 3a, and 3b protein in
PDAC tissues was observed in the cell nuclei with dif-
fuse and/or various staining patterns by immunohisto-
chemistry, while there was no positive staining in the
adjacent normal tissues (Figure 1). The expression rates
of DNMT1, DNMT3a and DNMT3b proteins were
48.9% (43/88), 23.9% (21/88) and 77.3% (68/88), respect-
ively, in the PDAC tissue samples. In addition, DNMT3b
expression significantly co-presented with DNMT3a ex-
pression (P = 0.025 with Kendall’s tau-b test), i.e., 95.2%
cases that were positive for DNMT3a were also positive
for DNMT3b, but not with DNMT1 expression.
Association of DNMT1, 3a or 3b expression with
clinicopathological characteristics and prognosis of the
patients
The association of DNM1, 3a, and 3b expression with
clinicopathological features of PDAC patients was de-
termined. The data showed that DNMT1 expression
was significantly associated with alcohol consumption,
whereas the other features did not show any associa-
tions (Additional file 1: Table S3). We followed the
patients for a median follow-up time of 18 months
Figure 3 Knockdown of DNMT1 and DNMT3b expression in PDAC cells. DNMT1 siRNA, DNMT3b siRNA, or their combination was transiently
transfected into PDAC cell lines and then subjected to qRT-PCR (A,B) and western blotting (C) analysis for DNMT1 and DNMT3b expression.
a, p < 0.05 compared with the untreated cells. b, p < 0.05 compared with the negative siRNA cells. The data are shown as the mean ± SD of six
independent experiments.
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two patients were lost the follow-up data. A univariate
survival analysis was used to assess the impact of clini-
copathological characteristics and DNMT1, DNMT3a
and DNMT3b expression on patient survival. As
shown in Figure 2, positive DNMT1 expression was
significantly associated with poor overall survival (the
median overall survival time: 11.6 months for positive
vs. 8.2 months for negative), a high TNM stage, poor
differentiation, lymph node metastasis and serum CEA
(Additional file 1: Table S4). The multivariate survivalanalysis, in which the significant variants from the uni-
variate survival analysis were inputted into the Cox re-
gression model, identified DNMT1 positive expression,
poor differentiation and serum CEA as independent
prognostic factors for poor overall survival (Additional
file 1: Table S5).
Effects of DNMT1 and DNMT3b siRNA on regulation of
PDAC cell viability, apoptosis, and cell cycle distribution
The rates of aberrant DNMT1 and DNMT3b expression
were much higher than that of DNMT3a in PDAC, and
Figure 4 Effects of DNMT1 and DNMT3b siRNA on cell viability (A), apoptosis (B) and cell cycle distribution (C). a, p < 0.05 compared
with the untreated cells. b, p < 0.05 compared with the negative siRNA-transfected cells. The data are shown as the mean ± SD of eight
independent experiments.
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Figure 5 Effects of DNMT1 and DNMT3b siRNA on the regulation of Bcl-2 (A), Bax (B) and CDKN1A (C) expression. a, p < 0.05 compared
with the untreated cells. b, p < 0.05 compared with the negative siRNA-transfected cells. The data are shown as the mean SD of six independent
experiments.
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tive for DNMT3b. Thus, we knocked down DNMT1
and 3b. It is possible that DNMT3a could also play a
role in PDAC progression. PDAC cell lines Panc-1
(poorly differentiated) and SW1990 (well-differentiated)
were assessed. As shown in Figure 3, both qRT-PCR and
Western blot data showed that transfection of DNMT1
and DNMT3b siRNA significantly reduced expression of
their corresponding mRNA and protein. Transfection of
either DNMT1 or DNMT3b siRNA significantly inhib-
ited the viability of PDAC cells and decreased the num-
ber of cells in the S-phase, increased the number of cells
in the G0/G1-phase, and induced apoptosis, with no
significant difference between DNMT1 and DNM3b
(Figure 4). Combination of DNMT1 or DNMT3b siRNA
did not have any synergistic effects.
Effect of DNMT1 and DNMT3b siRNA on the modulation
of CDKN1A, Bcl-2, and Bax expression
The expression of the cell cycle-related molecule
CDKN1A and the apoptosis-related molecule Bcl-2 and
Bax was detected by qRT-PCR. As shown in Figure 5,
expression of CDKN1A and Bax mRNA was significantly
upregulated in the DNMT1 siRNA, DNMT3b siRNA,
and DNMT1 +DNMT3b siRNA groups, whereas Bcl-2
mRNA was not significantly changed in all groups. How-
ever, the combination of DNMT1 and DNMT3b siRNA
did not have a synergistic effect. Additionally, the methy-
lation status of the Bax promoter was determined by
methylation-specific PCR (MSP). The demethylation ef-
fects of either DNMT1 or DNMT3b siRNA or their
combination are shown in Figure 6. These results sug-
gest that upregulated Bax mRNA expression may be due
to DNA demethylation.
Discussion
In the current study, we showed that the altered expres-
sion of DNMT1, 3a, and 3b was associated with PDAC
tumorigenesis and progression. Specifically, aberrant ex-
pression of DNMT1, 3a and 3b proteins was found in
PDAC tissues, and DNMT1 expression was significantly
associated with alcohol consumption and poor survivalFigure 6 Demethylation of Bax gene promoter was determined by M
combination was transiently transfected into PDAC cell lines. M, Methof PDAC patients. Knockdown of DNMT1 and DNMT3b
expression significantly inhibited the viability of PDAC
cells, decreased the number of cells in the S-phase, in-
creased the number of cells in the G0/G1-phase, induced
apoptosis, upregulated the mRNA expression of the cell
cycle-related CDKN1A gene and the pro-apoptotic Bax
gene, and demethylated Bax promoter DNA. Although a
synergistic effect of DNMT1 and DNMT3b siRNA
knockdown was not observed, DNMT silencing may be a
potential novel treatment strategy for PDAC.
Previous studies have demonstrated that hypermethyla-
tion of tumor suppressor gene promoters is crucial for
cancer initiation and progression [21]. Many CpG islands
in the gene promoters have been reported to be hyper-
methylated in PDAC [22], such as SPARC [23], CDKN2A
(p16) [24], RASSF1A [25], WWOX [25] and CXCR4 [26].
It has been speculated that the aberrant hypermethyla-
tion of tumor suppressor genes could be caused by ab-
normal upregulation of DNMT expression. In previous
studies, it was shown that the overexpression of DNMT1
[16,17] and DNMT3a [26] in PDAC tissues was associ-
ated with poor overall survival, but the association data
were inconsistent. In the current study, expression of
DNMT1, 3a and 3b proteins was simultaneously analyzed
in PDAC tissues and a more detailed investigation of
clinicopathological characteristics was performed. A
comprehensive knowledge about the pathogenic charac-
teristics of DNMTs involved in PDAC tumorigenesis was
gathered and our data indicate that overexpression of
DNMT1 and DNMT3b play a key role in PDAC tumori-
genesis and progression.
Hypermethylation of tumor suppressor genes is caused
by aberrant up-regulation of DNMT protein expression
and enzyme activity. Thus, many researchers have tar-
geted DNTM as a novel treatment strategy for tumors In
addition to cytosine analogues capable of trapping
DNMTs onto DNA, inhibition of DNMT mRNA expres-
sion through siRNA [15,27], antisense [15], irradiation
[28,29] and mediation through the Hedgehog pathway
[18] have been explored in previous studies. Some stud-
ies have also investigated the synergistic knockdown of
DNMT1 and DNMT3b [27,30,31]. In fact, our data didSP method after DNMT1 siRNA, DNMT3b siRNA, or their
ylation. U, Un-methylation.
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DNMT1 and DNMT3b siRNA in PDAC cells. These re-
sults were in agreement with previous studies in breast
[31] and PDAC cell lines [27], as well as in lung, esopha-
geal cancer, and malignant pleural mesothelioma cells
[32]. In contrast, other studies have shown a synergistic
effect in an ovarian cancer CP70 cell line [33], a cholan-
giocarcinoma QBC-939 cell line [31] and a colorectal
cancer cell line [34]. We speculated that this discrepancy
might be attributed to different hypermethylation mecha-
nisms in the different types of cancers. For example,
PDAC may have its own gene methylation profile during
tumorigenesis and progression [35,36]. Thus, further
in vivo studies are needed to confirm whether there is a
synergistic effect after combination of DNMT1 and
DNMT3b siRNA in PDAC.
As stated, DNMT1 and DNMT3b siRNA transfection
reduced PDAC cell viability, arrested cells at the G0/G1-
phases, decreased the number of cells at the S-phase of
the cell cycle and induced apoptosis of PDAC cells. In
order to explore the associated mechanism, we analyzed
the expression of Bcl-2 and Bax mRNA [37]. In this
study, Bax mRNA was significantly upregulated, while
Bcl-2 mRNA was not altered. This may have been due to
demethylation of the Bax gene promoter after DNMT1
and DNMT3b siRNA transfection. This finding is in
agreement with the hypothesis that Bax may be more
vulnerable to environmental factors than Bcl-2 in PDAC
[38]. In addition, the expression of CDKN1A mRNA was
analyzed because CDKN1A mediates cell cycle arrest in
response to the p53 checkpoint pathway during PDAC
tumorigenesis [39-41]. CDKN1A mRNA was significantly
upregulated after DNMT1 and DNMT3b siRNA trans-
fection. The results were consistent with previous studies
showing that DNMT inhibition led to a rapid upregula-
tion of CDKN1A expression [42].
The results of the present study demonstrated that
DNMT1, 3a and 3b proteins were highly expressed in
PDAC tissues, suggesting that DNMTs may be targets
for carcinogenic environmental factors to affect tumor
suppressor gene methylation. Knockdown of DNMT ex-
pression is a potential strategy for PDAC treatment.Additional file
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